Since RANK/RANKL/OPG signaling appears to play a role in the development of breast cancer and since RANKL inhibition may be a novel chemoprevention strategy in women at an increased breast cancer risk, this pathway will remain under investigation of present and future trials. Here, TNFRSF11A is linked to breast carcinoma.